Business
Fresenius Medical Care highlights real-world advances in hemodiafiltration and AI at ASN Kidney Week 2025
Fresenius Medical Care AG (FME), the world's leading provider of products and services for people with kidney diseases, will present new research showing how hemodiafiltration (HDF) is associated with improved outcomes for kidney patients and how innovations in artificial intelligence (AI) can support clinicians in daily care at the American Society of Nephrology (ASN) Kidney Week 2025, November 5-9 in Houston.
About this update from Fresenius Medical Care Ag
[{"type":"list","items":[{"val":[{"type":"text","content":"Fresenius Medical Care researchers will present multiple abstracts that demonstrate proven, real-world benefits of hemodiafiltration (HDF), with one accepted as an oral presentation.","length":182,"tagName":"p"}]},{"val":[{"type":"text","content":"Oral presentation highlights the association between HDF and reduced risk of cardiovascular and fluid-related hospitalization outcomes.","length":140,"tagName":"p"}]},{"val":[{"type":"text","content":"Research shows how artificial intelligence is moving from theory into practice, supporting clinicians and patients in daily kidney disease care.","length":144,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":466,"olType":false},{"type":"text","content":"BAD HOMBURG, Germany, Oct. 30, 2025 /PRNewswire/ -- Fresenius Medical Care AG (FME), the world's leading provider of products and services for people with kidney diseases, will present new research showing how hemodiafiltration (HDF) is associated with improved outcomes for kidney patients and how innovations in artificial intelligence (AI) can support clinicians in daily care at the American Society of Nephrology (ASN) Kidney Week 2025, November 5-9 in Houston.","length":470,"tagName":"p"},{"type":"image","alt":"Fresenius Medical Care (PRNewsfoto/Fresenius Medical Care North Am)","displaySize":"","headline":null,"caption":"Fresenius Medical Care (PRNewsfoto/Fresenius Medical Care North Am)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":86,"url":"https://media.zenfs.com/en/prnewswire.com/1ea334d2fed6b92c9bd382003cb7c081"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/CAPs.jZA.Pm6wlpD_VdyoQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE1MjtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/1ea334d2fed6b92c9bd382003cb7c081","width":400,"height":86}},"href":"https://mma.prnewswire.com/media/655917/FMC_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""This research reflects Fresenius Medical Care's commitment to patient-centered innovation, demonstrating how advanced therapies like hemodiafiltration can be tailored to improve outcomes in real-world settings," said Frank Maddux, MD, Global Chief Medical Officer at Fresenius Medical Care. "By applying novel physical principles to kidney replacement therapy, we ar...